Business | Thomson Reuters | Thursday April 21, 2016
New heart drugs hailed as breakthrough treatments by researchers are struggling to gain traction among prescribing doctors, posing a headache for makers such as Novartis, which reported more weak sales for its Entresto medicine on Thursday.
www.ndtv.com/business